Aktienanalyse wird geladen …
DGX · NYSE · Diagnostics & Research · USA
236,59 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 11,04 Mrd. | 992 Mio. | 8,75 $ | 113 Mio. | 0,4 Mio · 0,3 % | 0,4 Mio · 0,3 % | 33,2 % | 9 % | 12,03 $ | 0,78 $ | 3,20 $ |
| 2024 | 9,87 Mrd. | 871 Mio. | 7,69 $ | 113 Mio. | 0,4 Mio · 0,3 % | 0,4 Mio · 0,3 % | 32,9 % | 8,8 % | 8,04 $ | 0,78 $ | 3,00 $ |
| 2023 | 9,25 Mrd. | 854 Mio. | 7,49 $ | 113 Mio. | 0,3 Mio · 0,3 % | 5,3 Mio · 4,7 % | 33 % | 9,2 % | 7,65 $ | 0,68 $ | 2,84 $ |
| 2022 | 9,88 Mrd. | 946 Mio. | 7,97 $ | 118 Mio. | 0,3 Mio · 0,3 % | 10,3 Mio · 8,8 % | 34,7 % | 9,6 % | 11,14 $ | 0,65 $ | 2,64 $ |
| 2021 | 10,79 Mrd. | 2 Mrd. | 15,55 $ | 128 Mio. | 0,3 Mio · 0,3 % | 8,3 Mio · 6,5 % | 39 % | 18,5 % | 14,30 $ | 0,62 $ | 2,48 $ |
| 2020 | 9,44 Mrd. | 1,43 Mrd. | 10,47 $ | 136 Mio. | 0,4 Mio · 0,3 % | 0,4 Mio · 0,3 % | 38,5 % | 15,2 % | 11,67 $ | 0,71 $ | 2,24 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,04 Mrd. | 320 Mio. | 2,86 $ | 112 Mio. | 10,5 % | 4,10 $ |
| Q1 2026 | 2,9 Mrd. | 252 Mio. | 2,25 $ | 112 Mio. | 8,7 % | 1,46 $ |
| Q4 2025 | 2,81 Mrd. | 245 Mio. | 2,17 $ | 112 Mio. | 8,7 % | 2,72 $ |
| Q3 2025 | 2,82 Mrd. | 245 Mio. | 2,17 $ | 113 Mio. | 8,7 % | 3,71 $ |
| Q2 2025 | 2,76 Mrd. | 282 Mio. | 2,50 $ | 113 Mio. | 10,2 % | 3,86 $ |
| Q1 2025 | 2,65 Mrd. | 220 Mio. | 1,95 $ | 113 Mio. | 8,3 % | 1,74 $ |
| Q4 2024 | 2,62 Mrd. | 222 Mio. | 1,96 $ | — | 8,5 % | 3,02 $ |
| Q3 2024 | 2,49 Mrd. | 226 Mio. | 2,00 $ | 113 Mio. | 9,1 % | 2,21 $ |
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch
Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Why Quest Diagnostics Holdings Stock Dropped Today
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services. Its offerings include laboratory testing for areas such as cancer, heart disease, diabetes, infectious diseases, and genetic conditions, along with services for drug and alcohol screening, risk assessment, and healthcare information technology. The company operates a broad network of laboratories and patient service centers across the United States, helping connect sample collection, analysis, and reporting within the medical care process. Quest Diagnostics Incorporated plays a central role in the healthcare market by providing data and laboratory insights that support diagnosis, treatment decisions, and ongoing health management.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest DGX und jede andere Aktie unbegrenzt.